ClinicalTrials.gg
CompletedNCT03363477Updated Dec 6, 2017

Study of Pharmacodynamic Equivalence of Enoxaparin Rovi to Clexane®, in Healthy Volunteers

A Phase 1 interventional study of Enoxaparin and Clexane in Healthy, sponsored by Rovi Pharmaceuticals Laboratories. Completed. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-12-06.

Sponsored by Rovi Pharmaceuticals Laboratories · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 2 months after the study started (first participant enrolled Sep 2015, registered Nov 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

To demonstrate the pharmacodynamic (PD) equivalence of enoxaparin Rovi (100 mg/mL) 100-mg SC injection to Clexane® (100 mg/mL) 100-mg SC injection in healthy volunteers.

As secondary objective, to evaluate the safety and tolerability of enoxaparin Rovi (100 mg/mL) in healthy volunteers.

Read the detailed description

This is a single-dose, randomized, double-blind, 2-period, 2 sequence crossover study. Subjects will be screened up to 30 days before the study begins and admitted to the clinic on Day -1 of Period 1 for baseline assessments. Before dosing on Day 1 of Period 1, subjects will be randomly assigned to a treatment sequence. Subjects will receive a single dose of study drug on Day 1 of each treatment period.

On Day 1 of Period 1, subjects will receive a single dose by subcutaneous route of the assigned study drug: enoxaparin (100 mg/mL) 100-mg SC injection manufactured by Rovi Spain, or Clexane (100 mg/mL) 100-mg SC injection manufactured by Sanofi EU; after an overnight fasting period of at least 10 hours. Subjects will continue fasting for at least 4 hours after study drug administration.

The washout period between administrations of study drug in each period will be at least 7 days.

On Day 1 of Period 2, subjects will cross over to receive the dose of the other drug, after an overnight fasting period of at least 10 hours. The total duration of the study will be approximately 6 weeks.

02

Conditions studied

  • Healthy

Keywords

  • antithrombotic
  • heparin
  • anticoagulant
  • low molecular weight heparin
  • pharmacodynamic equivalence
03

In context

Lead sponsor

Rovi Pharmaceuticals Laboratories is the lead sponsor of 19 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject provides (approved by an Independent Ethical Committee (IEC)) before any study specific evaluation is performed.
  2. Subject is between the ages of 18 and 45 years, inclusive.
  3. All female subjects must have a negative pregnancy test at Screening and upon check-in to the clinic.
  4. Women of must use or have used one of the following acceptable methods: Surgical sterilization (bilateral tubal ligation, hysterectomy, bilateral oophorectomy) for at least 6 months before the first dose of study drug;Intrauterine device in place for at least 3 months before the first dose of study drug; or barrier method (condom, diaphragm) for at least 21 days before the first dose of study drug and throughout the study.
  5. Subject has a between 18 and 30 kg/m2, inclusive.
  6. Subject is able and willing to abstain from alcohol from 48 hours before the first dose of study drug through the end of the study.
  7. Subject has no abnormalities in medical history, vital sign measurements, or physical examination findings.
  8. Subject has computerized 12-lead (ECG) results showing no signs of clinically relevant pathology or deviations, as judged by the investigator.
  9. Subject has hematology, serum chemistry, coagulation, and urinalysis test results within the reference ranges ( ≥7.5 mmol/L and ≥8.5 mmol/L for female and male, respectively) or showing no clinically relevant deviations, as judged by the investigator. at screening have to be within the normal range.
  10. Subject is a nonsmoker or has quit smoking at least 6 months before the first dose of study drug.

Exclusion criteria

Exclusion Criteria:

Subjects are excluded from the study if any of the following criteria are met:

  1. Subject has active or recurring skin, head, ears, eyes, nose, throat, respiratory, cardiovascular, gastrointestinal, endocrine/metabolic, genitourinary, neurologic, hematologic, musculoskeletal, immunologic, allergic, psychological/psychiatric, or other disease requiring medical treatment.
  2. Female subject with weight \< 45 kg or male subject with weight \< 57 kg.
  3. Subject is a woman who is pregnant or breastfeeding.
  4. Subject has systolic blood pressure greater than 150 mm Hg or diastolic blood pressure greater than 90 mm Hg at Screening (confirmed upon repeat measurement).
  5. Subject has a calculated (Cockroft \& Gault formula) less than 80 mL/minute and the value does not return to within reference range upon retest.
  6. Subject has \<7.5 mmol/L and \<8.5 mmol/L for female and male, respectively.
  7. Subject has an active of any type other than nonmelanomatous skin malignancies.
  8. Subject has any history of alcohol abuse or drug addiction.
  9. Subject has any history of relevant drug and/or food allergies.
  10. Subject has used an drug within 60 days before the first dose of study drug.
  11. Subject has used any prescription drugs (with special attention to antiplatelet or anticoagulant medication, eg, acetyl salicylic acid, NSADs, clopidogrel, warfarin, acenocumarol, heparin, low molecular weight heparin, dabigatran, rivaroxaban, apixaban) or over-the-counter medication that may affect coagulation (including aspirin or NSAIDs) within 4 weeks before dosing, or any other over-the-counter medication (including vitamins, herbal supplements, or dietary supplements) within 2 weeks before dosing.
  12. Subject has donated or lost 550 mL or more of blood (including plasmapheresis) within 60 days before the first dose of study drug.
  13. Subject has a positive test result for drugs of abuse (opiates, methadone, cocaine, amphetamines, cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants, oxycodone), cotinine, or alcohol.
  14. Subject has a positive test result for (1 or 2) antibody, surface antigen, or virus antibody.
  15. Subject has any illness within 5 days before the first dose of study drug.
  16. Subject has a positive test for fecal occult blood at Screening.
  17. Subject has any history and/or current conditions of bleeding tendency such as: active bleeding, known bleeding diathesis or hemostatic defects due to severe hepatic or renal disease; recent gastrointestinal or genitourinary bleeding (10 days before study entry) women of with normal cyclic bleeding which is not considered as heavy menstruation by the investigator, are allowed for inclusion; diabetic hemorrhagic retinopathy, or other hemorrhagic ophthalmic conditions.
  18. Subject has a known history or family history of any relevant congenital or acquired coagulation disorder (eg, hemophilia, von Willebrand-Jürgens syndrome, or activated protein C resistance based upon Factor V Leiden mutation).
  19. Subject has a history of thrombocytopenia, including heparin induced thrombocytopenia.
  20. Subject has a known history of to drugs with a similar chemical structure to enoxaparin sodium (eg, unfractionated heparin, low molecular weight heparin) or to pork products.
  21. Subject is a member of the professional or ancillary personnel involved in the study.
  22. Subject is deemed not suitable for entry into the study in the opinion of the investigator.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    AB treatment sequence

    Period 1-Test Treatment A: enoxaparin (100 mg/mL) 100-mg SC injection, manufactured by Rovi (Spain) Period 2-Reference Treatment B: Clexane (100 mg/mL) 100-mg SC injection, manufactured by Sanofi (EU)

    Drug: Enoxaparin · Drug: Clexane

  • Active comparator
    BA treatment sequence

    Period 1-Reference Treatment B: Clexane (100 mg/mL) 100-mg SC injection, manufactured by Sanofi (EU) Period 2-Test Treatment A: enoxaparin (100 mg/mL) 100-mg SC injection, manufactured by Rovi (Spain)

    Drug: Enoxaparin · Drug: Clexane

Interventions

  • Also known as: Enoxaparin (Rovi, Spain), enoxaparin sodium

  • Also known as: Clexane (Sanofi, EU), enoxaparin sodium

06

What researchers measure

Primary outcomes

  1. AUEC0-inf for anti-FXa

    area under the effect curve (AUEC) from time 0 to infinity, for anti-FXa

    Time frame: Day -1 (Periods 1 and 2), before dosing (Pre-dose), and between 0.5 and 36 hours after dosing on Day 1 (Periods 1 and 2)

  2. AUEC0-T for anti-FXa and anti-FIIa

    area under the effect curve (AUEC) from time 0 to the last measured activity (T), for anti-FXa and anti-FIIa

    Time frame: Day -1 (Periods 1 and 2), before dosing (Pre-dose), and between 0.5 and 36 hours after dosing on Day 1 (Periods 1 and 2)

  3. Amax for anti-FXa and anti-FIIa

    peak effect for anti-FXa activity (anti-FXamax), and anti-FIIa activity (anti-FIIamax)

    Time frame: Day -1 (Periods 1 and 2), before dosing (Pre-dose), and between 0.5 and 36 hours after dosing on Day 1 (Periods 1 and 2)

Secondary outcomes

  1. RAUEC

    ratio of AUEC0-T of anti-FXa to anti-FIIa

    Time frame: Day -1 (Periods 1 and 2), before dosing (Pre-dose), and between 0.5 and 36 hours after dosing on Day 1 (Periods 1 and 2)

  2. Amax for TFPI levels

    peak effect activity (Amax) forTissue factor pathway inhibitor (TFPI)

    Time frame: Day -1 (Periods 1 and 2), before dosing (Pre-dose), and between 0.5 and 36 hours after dosing on Day 1 (Periods 1 and 2)

  3. AUEC0-T for TFPI levels

    Area under the effect curve (AUEC) from time 0 to the last measured activity (T) forTissue factor pathway inhibitor (TFPI)

    Time frame: Day -1 (Periods 1 and 2), before dosing (Pre-dose), and between 0.5 and 36 hours after dosing on Day 1 (Periods 1 and 2)

  4. AUEC0-inf for TFPI levels

    Area under the effect curve (AUEC) from time 0 to infinity forTissue factor pathway inhibitor (TFPI)

    Time frame: Day -1 (Periods 1 and 2), before dosing (Pre-dose), and between 0.5 and 36 hours after dosing on Day 1 (Periods 1 and 2)

  5. Tmax for anti-FXa and anti-FIIa

    time of observed maximum measured plasma activity for anti-FXa and anti-FIIa

    Time frame: Day -1 (Periods 1 and 2), before dosing (Pre-dose), and between 0.5 and 36 hours after dosing on Day 1 (Periods 1 and 2)

  6. t1/2 for anti-FXa and anti-FIIa

    apparent first order terminal elimination half-life for anti-FXa and anti-FIIa

    Time frame: Day -1 (Periods 1 and 2), before dosing (Pre-dose), and between 0.5 and 36 hours after dosing on Day 1 (Periods 1 and 2)

  7. CL/F for anti-FXa and anti-FIIa

    apparent plasma clearance after extravascular administration for anti-FXa and anti-FIIa

    Time frame: Day -1 (Periods 1 and 2), before dosing (Pre-dose), and between 0.5 and 36 hours after dosing on Day 1 (Periods 1 and 2)

  8. MRT for anti-FXa and anti-FIIa

    mean residence time for anti-FXa and anti-FIIa

    Time frame: Day -1 (Periods 1 and 2), before dosing (Pre-dose), and between 0.5 and 36 hours after dosing on Day 1 (Periods 1 and 2)

  9. Adverse Events (AEs)

    All treatment emergent AEs (TEAEs), relationship of TEAEs to study drug, severity of TEAEs, treatment emergent serious AEs, relationship of treatment emergent serious AEs to study drug, and TEAEs leading to study drug discontinuation. The frequency of TEAEs will be summarized by system organ class and preferred term

    Time frame: from Informed Consent signature until 14 days after the last study drug administration (independently of the period)

  10. hematology

    clinical laboratory results

    Time frame: at Screening, Day -1 (Period 1 only), and Day 3 (Period 2 only) and at the follow up visit (Day 7 of Period 2 only)

  11. Serum chemistry

    measurements of a variety of compounds in the serum layer of blood

    Time frame: at Screening, Day -1 (Period 1 only), and Day 3 (Period 2 only) and at the follow up visit (Day 7 of Period 2 only)

  12. Coagulation

    Prothrombin time (reported in seconds) and activated partial thromboplastin time (aPTT)

    Time frame: at Screening, Day -1 (Period 1 only), and Day 3 (Period 2 only) and at the follow up visit (Day 7 of Period 2 only)

  13. Urianalysis

    measurements of a variety of compounds in urine

    Time frame: at Screening, Day -1 (Period 1 only), and Day 3 (Period 2 only) and at the follow up visit (Day 7 of Period 2 only)

  14. Blood presure

    systolic and diastolic blood presure recorded after the subject had been resting for at least 5 minutes

    Time frame: at Screening, Day -1 (Period 1 only), and before dosing (Pre-dose) and 0.5 hours after dosing on Day 1 (Periods 1 and 2)

  15. Pulse rate

    recorded after the subject had been resting

    Time frame: at Screening, Day -1 (Period 1 only), and before dosing (Pre-dose) and 0.5 hours after dosing on Day 1 (Periods 1 and 2)

  16. Respiratory rate

    measured subsequently to pulse rate

    Time frame: at Screening, Day -1 (Period 1 only), and before dosing (Pre-dose) and 0.5 hours after dosing on Day 1 (Periods 1 and 2)

  17. Tympanic temperature

    measured subsequently to pulse rate

    Time frame: at Screening, Day -1 (Period 1 only), and before dosing (Pre-dose) and 0.5 hours after dosing on Day 1 (Periods 1 and 2)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2015 to primary completion in Dec 2015, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2017
First posted
Dec 6, 2017
StartActual
Sep 25, 2015
Primary completionActual
Dec 1, 2015
CompletionActual
Dec 1, 2015
Last update
Dec 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03363477
Lead sponsor
Rovi Pharmaceuticals Laboratories
Collaborators
PRA Health Sciences
Responsible party
Sponsor
First posted
Dec 6, 2017
Start date
Sep 25, 2015
Primary completion
Dec 1, 2015
Completion
Dec 1, 2015
Last update
Dec 6, 2017

Study contacts

Maria Velinova, MD, PhD
principal investigator · PRA Health Sciences (PRA) - Early Development Services (EDS)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Enoxaparin · Enoxaparin sodium

Start the discussion